Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: AMGN amgen.com
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics across oncology, cardiovascular disease, inflammation, rare diseases, and obesity. The company's portfolio includes more than two dozen marketed products spanning monoclonal antibodies, bispecific T-cell engager (BiTE) molecules, biosimilars, and small molecules. Key growth franchises include Repatha (cholesterol), EVENITY (osteoporosis), TEZSPIRE (severe asthma, co-developed with AstraZeneca), UPLIZNA (rare autoimmune diseases), BLINCYTO (acute lymphoblastic leukemia), and IMDELLTRA (small cell lung cancer). Amgen is also advancing MariTide, a differentiated antibody-peptide conjugate for obesity and related conditions, through an extensive Phase 3 program. The company operates a large-scale biologics manufacturing network and maintains a deep biosimilar pipeline targeting major reference biologics. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index. Updated
Walmart is sending shareholders about $1.97 billion, or 24.75 cents a share, with the money arriving September 8. Amgen is close behind at roughly $1.36 billion, and its $2.52 a share is the biggest per-share payment on today's list.
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that…
Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Every dividend dollar sitting in a taxable account quietly hands a portion of itself to the IRS year after year, and after two decades that quiet cost compounds into a number most…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper…
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.…
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place…
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
Most dividend investors chase yield and end up watching their payouts shrink or disappear. These five stocks flip that script by pairing decades of uninterrupted payments with the cash flow coverage to…
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics across oncology, cardiovascular disease, inflammation, rare diseases, and obesity.
24/7 Wall St.'s 12-month price target for AMGN is $476.46, rated Buy. The Wall Street consensus target is $394.98. AMGN price prediction →
